Aspirin for primary prevention of cardiovascular disease: A meta-analysis with a particular focus on subgroups

0511513 - ÚI 2020 RIV GB eng J - Článek v odborném periodiku
Gelbenegger, G. - Postula, M. - Pecen, Ladislav - Halvorsen, S. - Lesiak, M. - Schoergenhofer, C. - Jilma, B. - Hengstenberg, C. - Siller-Matula, J. M.
Aspirin for primary prevention of cardiovascular disease: A meta-analysis with a particular focus on subgroups.
BMC Medicine. Roč. 17, č. 1 (2019), č. článku 198. ISSN 1741-7015. E-ISSN 1741-7015
Institucionální podpora: RVO:67985807
Klíčová slova: Aspirin * Cancer * Cardiovascular disease * Major adverse cardiovascular event * Major bleeding * Meta-analysis * Myocardial infarction * Primary prevention * Stroke
Obor OECD: Cardiac and Cardiovascular systems
Impakt faktor: 6.782, rok: 2019
Způsob publikování: Open access

BACKGROUND: The role of aspirin in primary prevention of cardiovascular disease (CVD) remains unclear. We aimed to investigate the benefit-risk ratio of aspirin for primary prevention of CVD with a particular focus on subgroups. METHODS: Randomized controlled trials comparing the effects of aspirin for primary prevention of CVD versus control and including at least 1000 patients were eligible for this meta-analysis. The primary efficacy outcome was all-cause mortality. Secondary outcomes included cardiovascular mortality, major adverse cardiovascular events (MACE), myocardial infarction, ischemic stroke, and net clinical benefit. The primary safety outcome was major bleeding. Subgroup analyses involving sex, concomitant statin treatment, diabetes, and smoking were performed. RESULTS: Thirteen randomized controlled trials comprising 164,225 patients were included. The risk of all-cause and cardiovascular mortality was similar for aspirin and control groups (RR 0.98, 95% CI, 0.93-1.02, RR 0.99, 95% CI, 0.90-1.08, respectively). Aspirin reduced the relative risk (RRR) of major adverse cardiovascular events (MACE) by 9% (RR 0.91, 95% CI, 0.86-0.95), myocardial infarction by 14% (RR 0.86, 95% CI, 0.77-0.95), and ischemic stroke by 10% (RR 0.90, 95% CI, 0.82-0.99), but was associated with a 46% relative risk increase of major bleeding events (RR 1.46, 95% CI, 1.30-1.64) compared with controls. Aspirin use did not translate into a net clinical benefit adjusted for event-associated mortality risk (mean 0.034%, 95% CI,-0.18 to 0.25%). There was an interaction for aspirin effect in three patient subgroups: (i) in patients under statin treatment, aspirin was associated with a 12% RRR of MACE (RR 0.88, 95% CI, 0.80-0.96), and this effect was lacking in the no-statin group, (ii) in non-smokers, aspirin was associated with a 10% RRR of MACE (RR 0.90, 95% CI, 0.82-0.99), and this effect was not present in smokers, and (iii) in males, aspirin use resulted in a 11% RRR of MACE (RR 0.89, 95% CI, 0.83-0.95), with a non-significant effect in females. Conclusions: Aspirin use does not reduce all-cause or cardiovascular mortality and results in an insufficient benefit-risk ratio for CVD primary prevention. Non-smokers, patients treated with statins, and males had the greatest risk reduction of MACE across subgroups.
Trvalý link: http://hdl.handle.net/11104/0301761